Biotek-snakken — Januar 2024
-
Bemærk at Ultimovacs løber op over for øjeblikket.
-
Bioporto jagter ny topchef til næste fase: For 2,5 år siden var han den rette person https://www.proinvestor.com/investornyt/1102534/bioporto-jagter-ny-topchef-til-naeste-fase-for-25-ar-siden-var-han-den-rette-person
-
Ultimovacs i mål – resultater kommer snart https://www.finansavisen.no/helse/2024/01/16/8083030/ultimovacs-i-mal-resultater-kommer-snart
-
Redeye’s Top Stock Picks for 2024
Yesterday, during a full-day event at Posthuset in Stockholm, Redeye revealed its top three stock picks for 2024 in the tech and life science sectors. We believe these companies will have a strong 2024, with a stacked list of triggers and solid fundamentals.
-
Unge biotekvirksomheder med et godkendt produkt https://www.proinvestor.com/boards/118022
-
XBRANE ANNOUNCES A RIGHTS ISSUE OF UNITS OF APPROXIMATELY SEK 343 MILLION
NOTICE OF EXTRA GENERAL MEETING IN XBRANE BIOPHARMA AB
-
XBRANE BIOPHARMA REGISTERS THREE NEW PATENTS IN SWEDEN
-
Curasight modtager milepælsbetaling på knap 3,5 mio. kr. fra partneren Curium https://www.proinvestor.com/investornyt/1106043/curasight-modtager-milepaelsbetaling-pa-knap-35-mio-kr-fra-partneren-curium
-
God morgen
-
Falder “kun” 75%….det er da til at føle på….vidste emissionen kom, det var ret tydeligt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind